Investigating the Effects of Systemically Administered Strontium Ranelate on Alveolar Bone Loss Histomorphometrically and Histopathologically on Experimental Periodontitis in Rats

Karakan, Nebi Cansın; Akpınar, Aysun; Göze, Fahrettin; Poyraz, Ömer

doi:10.1902/jop.2016.160227

Cited by 22 publications

(39 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, a previous study demonstrated that strontium ranelate was also unable to prevent ligature-induced BL in normal rats at a dose of 625 mg/kg/d and only yielded significant reduction in BL at a higher dose of 900 mg/kg/d. 20 In contrast, another study, using a much smaller dose of strontium ranelate (100 mg/kg/d), showed that this agent decreased BL at 7 days after ligature placement, when compared to an untreated group, emphasizing that the actual effects of strontium ranelate on ligature-induced alveolar BL are still controversial. Interestingly, during the initial phase of administration (at 10 days), normal animals that received strontium ranelate exhibited ~15% more TBA than the untreated ones in both unligated (67.5% vs 77.5%) and ligated teeth (56.2% vs 63.8%).…”

Section: Discussionmentioning

confidence: 98%

“…In the current study, there were no observed differences in BL for strontium ranelate‐treated and untreated rats with normal levels of estrogen, at any of the experimental timepoints. Accordingly, a previous study demonstrated that strontium ranelate was also unable to prevent ligature‐induced BL in normal rats at a dose of 625 mg/kg/d and only yielded significant reduction in BL at a higher dose of 900 mg/kg/d . In contrast, another study, using a much smaller dose of strontium ranelate (100 mg/kg/d), showed that this agent decreased BL at 7 days after ligature placement, when compared to an untreated group, emphasizing that the actual effects of strontium ranelate on ligature‐induced alveolar BL are still controversial.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

Marins

Napimoga

Malta

et al. 2019

J of Periodontal Research

View full text Add to dashboard Cite

Background and objectives Strontium ranelate is a medication indicated for the treatment of osteoporosis that presents concomitant anti‐resorptive and osteoanabolic dual biological activity. However, the effects of strontium ranelate on alveolar bone have been poorly explored. Furthermore, to date, there are no data on the effects of this medication on alveolar bone loss (BL) during conditions of estrogen deficiency. Therefore, the aim of this study was to evaluate the effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats. Methods Ninety‐six rats were assigned to one of the following groups: sham‐surgery + water (estrogen‐sufficient; n = 24); ovariectomy + water (estrogen‐deficient; n = 24), sham‐surgery + strontium ranelate (ranelate/estrogen‐sufficient; n = 24) and; ovariectomy + strontium ranelate (ranelate/estrogen‐deficient; n = 24). The rats received strontium ranelate or water from the 14th day after ovariectomy until the end of the experiment. On the 21st day after ovariectomy, one first mandibular molar received a ligature, while the contralateral tooth was left unligated. Eight rats per group were killed at 10, 20, and 30 days after ligature placement. Bone loss (BL) and trabecular bone area (TBA) were analyzed in the furcation area of ligated and unligated teeth at all experimental times by histometry. Tartrate‐resistant acid phosphatase (TRAP) positive cells and immunohistochemical staining for osteocalcin (OCN), osteopontin (OPN), osteoprotegerin (OPG), and receptor activator of NF‐КB ligand (RANKL) were assessed in the ligated teeth at 30 days after ligature placement. Results At 10 and 30 days, ligated teeth of the estrogen‐deficient group exhibited higher BL, when compared to all other groups (P < .05). At 10 days, TBAs were higher in the unligated teeth of strontium ranelate‐treated groups, when compared to those of untreated groups (P < .05). At 30 days, the ligated teeth of the estrogen‐deficient group exhibited lower TBA than the other groups (P < .05). There were no differences among groups regarding the number of TRAP‐stained cells (P < .05). The strontium ranelate‐treated groups exhibited lower expressions of OCN and RANKL than the untreated groups (P < .05). The estrogen‐sufficient group presented higher staining for OPG than both treated and untreated estrogen‐deficient groups (P < .05). Conclusions Strontium ranelate prevented ligature‐induced BL in an estrogen‐deficiency condition and, to a certain extent, increased TBA in the presence and absence of periodontal collapse in states of estrogen deficiency and estrogen sufficiency. Furthermore, strontium ranelate also affected the expression of bone markers, appearing to have acted predominantly as an anti‐resorptive agent.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 98%

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

Marins

Napimoga

Malta

et al. 2019

J of Periodontal Research

View full text Add to dashboard Cite

show abstract

“…Er et al suggested that Sr 2+ was not toxic to hPDLCs and Romer et al reported that Sr 2+ could promote cell proliferation and suppress IL‐6 expression in hPDLCs. Karakan et al found that Sr 2+ could prevent the alveolar bone loss in experimental periodontitis. Our previous studies also suggested that biomaterial modified with Sr 2+ could significantly stimulate the osteogenesis/cementogenesis‐related gene expression of hPDLCs and provide a more significant periodontal regeneration in the osteoporotic animal model …”

Section: Introductionmentioning

confidence: 99%

Strontium ion attenuates lipopolysaccharide‐stimulated proinflammatory cytokine expression and lipopolysaccharide‐inhibited early osteogenic differentiation of human periodontal ligament cells

Wei

Jiang

Zhou

et al. 2018

J of Periodontal Research

View full text Add to dashboard Cite

show abstract

“…SR has been examined in numerous studies, which have verified its distinct effects on bone metabolism. It has been reported to increase bone mass and to suppress the activity of osteoclasts, thus preventing bone loss (25). In another previous study, SR has been observed to stimulate bone collagen synthesis and to decrease the expression of functional osteoclast markers, including carbonic anhydrase II and vitronectin receptor (26).…”

Section: Introductionmentioning

confidence: 94%

Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice

et al. 2018

View full text Add to dashboard Cite

Aseptic loosening and menopause‑induced osteoporosis are caused by an imbalance between bone formation and osteolysis. With an aging population, the probability of simultaneous occurrence of such conditions in an elderly individual is increasing. Strontium ranelate (SR) is an anti‑osteoporosis drug that promotes bone formation and inhibits osteolysis. The present study compared the effects of SR with those of the traditional anti‑osteoporosis drug alendronate (ALN) using an ovariectomized mouse model of osteolysis. The degree of firmness of the prosthesis and the surrounding tissue was examined, a micro‑CT scan of the prosthesis and the surrounding tissue was performed, and the levels of inflammatory and osteogenic and osteoclast factors were examined. It was observed that treatment with SR and ALN improved the bond between the prosthesis and the surrounding bone tissue by reducing the degree of osteolysis, thus improving the quality of bone around the prosthesis. SR increased the secretion of osteocalcin, runt‑related transcription factor 2 and osteoprotegerin (OPG). It additionally decreased the expression of the receptor activator of nuclear factor‑κB ligand (RANKL) and consequently increased the protein ratio OPG/RANKL, whereas ALN exhibited the opposite effect. Furthermore, SR and ALN suppressed tumor necrosis factor‑α and interleukin‑1β production, with SR exerting a more marked effect. The present results demonstrate that SR and ALN may stimulate bone formation and inhibit bone resorption in the ovariectomized mouse model of wear particle‑mediated osteolysis, with SR demonstrating better effects compared with ALN.

show abstract

Investigating the Effects of Systemically Administered Strontium Ranelate on Alveolar Bone Loss Histomorphometrically and Histopathologically on Experimental Periodontitis in Rats

Abstract: It can be concluded that SR can reduce RANKL activity and osteoclast numbers, as well as ABL.

Cited by 22 publications

References 48 publications

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

Effects of strontium ranelate on ligature‐induced periodontitis in estrogen‐deficient and estrogen‐sufficient rats

Strontium ion attenuates lipopolysaccharide‐stimulated proinflammatory cytokine expression and lipopolysaccharide‐inhibited early osteogenic differentiation of human periodontal ligament cells

Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice

Contact Info

Product

Resources

About